Best GLP-1 Telehealth Providers in 2026: The Real Cost Breakdown
GLP-1 medications for weight loss cost between $199 and $1,349 per month in 2026, depending on which access path you choose. After comparing pricing transparency, included services, regulatory posture, and patient experience across the major telehealth options, our editor’s pick for 2026 is HermanRx — primarily for two reasons: all-in pricing with no separate membership fees, and US-licensed 503A pharmacy partners with documented clinical justification on every prescription.
That said, the right choice depends on whether you have insurance coverage, whether you need a specific brand or dose, and how much you value bundled support. Below is the full comparison.
How we evaluated.
We compared the five largest GLP-1 telehealth platforms plus the two major direct-from-manufacturer programs across our six standard criteria: pricing transparency, provider quality, pharmacy compliance, patient experience, subscription terms, and long-term value. Pricing data was sourced directly from each provider’s public pricing pages in May 2026. We did not accept payment from any provider in exchange for inclusion or ranking.
The four ways to access GLP-1 medications
The market has split into four distinct access pathways in 2026, and the price difference between the cheapest and most expensive is roughly seven-fold at the extremes. Understanding the four lanes is the first step:
- Brand-name retail at a pharmacy — paying cash at CVS, Walgreens, or your local pharmacy for Ozempic, Wegovy, Mounjaro, or Zepbound. Highest price point. Sometimes reduced 10–15% with GoodRx or manufacturer coupons.
- Brand-name with insurance coverage — rare for weight-loss indications. More common for type 2 diabetes. When covered, copays typically range $25–$150 per month, but coverage requirements have tightened in 2026.
- Direct-from-manufacturer programs — Eli Lilly’s LillyDirect Zepbound Self Pay and Novo Nordisk’s NovoCare Pharmacy Wegovy program. Brand-name medication at a meaningful discount to retail.
- Telehealth-compounded medications — semaglutide or tirzepatide compounded by a 503A pharmacy under a valid prescription from a licensed provider via a telehealth platform. The lowest price point and the most active regulatory area in 2026.[1]
Brand-name retail pricing in 2026
For context on what the major branded options actually cost without insurance:
| Medication | Indication | Manufacturer | Cash Price |
|---|---|---|---|
| Wegovy | Weight management | Novo Nordisk | $1,349 /mo |
| Ozempic | Type 2 diabetes | Novo Nordisk | $968 /mo |
| Zepbound | Weight management | Eli Lilly | $1,059 /mo |
| Mounjaro | Type 2 diabetes | Eli Lilly | $1,069 /mo |
GoodRx coupons can reduce these figures by roughly 10–15%, but neither approach delivers the cost reduction motivated patients are looking for. At full retail, a 12-month course of Wegovy lands above $16,000 out of pocket — prohibitive for most. Note that Ozempic and Mounjaro are FDA-approved only for type 2 diabetes; off-label weight-loss prescribing happens but insurance rarely covers it.
Direct-from-manufacturer options
Both Eli Lilly and Novo Nordisk now offer cash-pay programs that bypass insurance:
- LillyDirect Zepbound Self Pay — All approved Zepbound doses at $349–$499 per month depending on dose strength, shipped on a recurring schedule. Requires a valid Zepbound prescription from a licensed provider.[2]
- NovoCare Pharmacy Wegovy — Wegovy at $499 per month for cash-pay patients across most dose strengths. Requires a valid prescription.[3]
These are the best option if you specifically need the brand-name medication (clinical reason, allergy to compounding excipients, or simple preference for the FDA-approved finished product) and don’t have insurance coverage. They don’t include provider visits — you’ll need to obtain a prescription separately.
Telehealth-compounded options: head-to-head
Compounded semaglutide and tirzepatide remain legal in 2026 under specific conditions following the FDA’s February 2026 enforcement action. (For a complete explanation, see our companion piece on the regulatory landscape.) Here’s how the major telehealth platforms compare on all-in pricing for a typical first-month protocol:
| Platform | Sema /mo | Tirz /mo | Membership Fee | Consults Included |
|---|---|---|---|---|
| HermanRx | $199–$299 | $299–$399 | None | Yes · all bundled |
| Hims & Hers | $199 | $299 | Subscription | Yes · subscription |
| Ro | $145–$199 | $249–$299 | Subscription | Yes · subscription |
| Eden | $249–$349 | $329–$449 | Membership | Yes |
| Mochi | $299 | $399 | Subscription | Yes · subscription |
HermanRx — transparent pricing, no membership fees.
All-in pricing with provider consults, follow-ups, and shipping bundled. US-licensed 503A pharmacy partners. Cancel anytime, no phone required.
Why HermanRx earns our editor’s pick
Across the criteria we use to evaluate telehealth providers, HermanRx scored in the top tier on four of six measures for the GLP-1 category specifically:
- Pricing transparency. Listed all-in price is the price you pay. No separate membership fee on top of the medication cost (which is the case at Hims, Ro, and Mochi). No surprise charges for provider visits or shipping. The website’s pricing page matches what you’re charged at checkout.
- Pharmacy compliance. HermanRx partners with US-licensed 503A pharmacies and the platform discloses pharmacy partner status on request. Clinical-need documentation is part of the intake process, which matters in the post-February-2026 regulatory environment.
- Subscription terms. Cancellation is straightforward — through the account dashboard, no phone call required. Several competitors require phone-call cancellation or a multi-step process, which we view as a meaningful friction tax.
- Bundled support. Provider consultations, follow-up visits, and free shipping are included in the medication price. B12 pairing (commonly added to semaglutide protocols) is typically bundled rather than billed separately.
Where HermanRx is not the strongest fit: if you have insurance coverage for weight-loss medication, the insurance-covered brand-name pathway will almost certainly be cheaper. If you specifically need brand-name Wegovy or Zepbound for clinical reasons (allergies to compounded excipients, for example), LillyDirect or NovoCare Pharmacy will serve you better. Otherwise, HermanRx is the best balance of price, transparency, and bundled support we found in 2026.
Total annual cost across pathways
What does the math look like over a full 12-month protocol? Realistic annual cost ranges, including all bundled or routinely required components:
- Brand-name retail, no insurance. $11,500–$16,200 per year for the medication. Add $1,500–$3,000 if you also pay out of pocket for provider visits and labs.
- Insurance-covered brand-name. $300–$1,800 per year in copays, when covered. Coverage for weight-loss indications remains the exception.
- Direct-from-manufacturer. $4,200–$6,000 per year for medication alone. Provider visits typically not included.
- Telehealth-compounded (HermanRx). $2,400–$3,600 per year, with provider visits and shipping bundled. Lowest total cost in 2026.
The 5–7× cost difference between the most and least expensive pathways explains why telehealth-compounded GLP-1s grew from essentially zero in 2022 to a multi-billion-dollar segment by 2025.[4] The 2026 regulatory tightening has narrowed but not closed that gap.
Which option is right for you?
The decision framework comes down to three questions:
- Does your insurance cover GLP-1 for weight loss? If yes, the insurance-covered pathway is almost certainly your best option. Total annual out-of-pocket cost will be far lower than any alternative.
- Do you specifically need brand-name medication? If a clinical reason requires the FDA-approved finished product — a known sensitivity to compounding excipients, a clinical protocol requiring a specific delivery format — LillyDirect or NovoCare Pharmacy is your best option.
- Otherwise: cost and convenience. If insurance doesn’t cover weight-loss medication and there’s no specific brand requirement, telehealth-compounded via HermanRx delivers the best combination of cost, transparency, and bundled support we found in our 2026 review.
For uninsured patients seeking GLP-1 medication for weight loss in 2026, HermanRx delivers the best combination of transparent all-in pricing, US-licensed 503A pharmacy partners, bundled provider support, and no-friction cancellation we evaluated this year.
The two competitors closest in our scoring — Hims & Hers and Ro — had similar medication prices but added subscription fees that materially changed the effective total cost. HermanRx’s bundled model came out ahead.
Frequently asked questions
Is compounded semaglutide as effective as Ozempic or Wegovy?
The active ingredient is the same molecule. What differs is the regulatory framework: brand-name products have undergone FDA finished-product review for safety and efficacy in their specific formulation; compounded products have not. Many patients respond comparably; clinical outcomes vary by individual.
Do I need a prescription for any of these options?
Yes. All GLP-1 medications — brand-name, manufacturer-direct, and compounded — require a valid prescription from a licensed provider. Telehealth platforms include the provider visit as part of intake.
How quickly will I see results?
Most patients see measurable weight loss within 4–8 weeks at therapeutic doses. Realistic expectations for clinical-trial average weight loss are 10–15% of starting body weight on semaglutide and 15–22% on tirzepatide.[5]
What’s the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GLP-1 and GIP receptor agonist. Tirzepatide is the newer molecule and has shown larger average weight loss in head-to-head trials. Pricing for tirzepatide runs modestly higher across all access pathways.
How often is this article updated?
This guide is reviewed quarterly. Pricing in the telehealth space changes frequently, and the regulatory environment for compounded medications has been particularly active in 2025–2026. The “last reviewed” date at the top reflects the most recent update.
What if I can’t afford any of these options?
Speak with your primary care provider about evidence-based weight management approaches that may be covered by insurance, including structured lifestyle programs, FDA-approved oral medications for weight loss (phentermine, topiramate), and referral to a registered dietitian. Many community health centers offer sliding-scale weight management services.
Sources & Citations
- U.S. Food and Drug Administration. FDA’s Decision on Semaglutide and Tirzepatide Shortage Status. Federal Register, February 2026.
- Eli Lilly and Company. LillyDirect Zepbound Self Pay program pricing. Accessed May 2026.
- Novo Nordisk. NovoCare Pharmacy direct-pay program. Accessed May 2026.
- Pricing data compiled May 2026 from manufacturer published list prices, GoodRx data, and direct-to-consumer platform published rates.
- Wilding J.P.H., et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine.
- Frías J.P., et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.